26 Jul 2013 15:08
26 July 2013
Immunodiagnostic Systems Holdings Plc
AGM Results
Immunodiagnostic Systems Holdings PLC ("IDS" or "the Company" or "the Group"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, today announces the results of its Annual General Meeting (the "Meeting") that was held at 2 p.m..
Trading update
Dr Anthony Martin, Non-executive Chairman, provided a business update at the Meeting and a copy of the trading statement has been made available on the Company's website.
Voting Results
All resolutions put to the meeting were duly passed.
For information, although all resolutions were passed on a show of hands, details of the proxy voting are shown below:
Resolution | Votes For (and discretion) | Votes For (and discretion) (as % of votes cast) | Votes Against (as % of votes cast) | Votes Withheld |
1. To receive the accounts for the financial year ended 31 March 2013 together with the reports of the Directors and of the Auditor thereon.
| 18,146,060 | 100.00 | 0.00 | 1,039,348 |
2. To declare a final dividend for the financial year ended 31 March 2013. | 18,146,060 | 100.00 | 0.00 | 1,039,348 |
3. To elect as a Director of the Company Mr Chris Yates. | 18,145,432 | 100.00 | 0.00 | 1,039,976 |
4. To re-elect as a Director of the Company Dr Patrik Dahlen. | 18,119,812 | 96.76 | 3.24 | 459,419 |
5. To re-elect as a Director of the Company Dr Burkhard Wittek. | 17,294,296 | 92.35 | 7.65 | 459,419
|
6. To re-appoint Ernst & Young LLP as Auditor of the Company. | 18,146,060 | 100.00 | 0.00 | 1,039,348 |
7. To authorise the Directors of the Company to determine the remuneration of the Auditor of the Company.
| 18,146,060 | 100.00 | 0.00 | 1,039,348 |
8. To approve the Directors' remuneration report for the financial year ended 31 March 2013. | 15,595,669 | 87.88 | 12.12 | 1,439,348 |
9. To authorise the Directors to allot relevant securities. | 18,145,432 | 100.00 | 0.00 | 1,039,976 |
10. To authorise the disapplication of pre-emption rights in accordance with section 570 of the Companies Act 2006. | 17,745,432 | 97.80 | 2.20 | 1,039,976 |
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the IDS website (www.idsplc.com).
For further information:
Immunodiagnostic Systems Holdings PLC | Tel : +44 (0)191 519 0660 |
Patrik Dahlen, Chief Executive Officer | |
Chris Yates, Finance Director
| |
Peel Hunt LLP | Tel : +44 (0)207 418 8900 |
James Steel | |
Dr Vijay Barathan | |
FTI Consulting |
Tel : +44 (0)207 831 3113 |
Ben Atwell | |
Simon Conway | |
Mo Noonan |
About Immunodiagnostic Systems Holdings PLC
The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.
http://www.idsplc.com